CRISPR/Cas9-based therapeutics (GenEdit/University of California)

N/A

Report date: 2025/01/26 18:07:56
NME

Base Information

Drug NameCRISPR/Cas9-based therapeutics (GenEdit/University of California)
Drug Alias NameCRISPR-Gold
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsFragile X SyndromeMuscular Dystrophy, Duchenne
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesGenEdit Inc
China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of California, BerkeleyGenEdit Inc
Inactive CompaniesN/A
Active IndicationsFragile X SyndromeMuscular Dystrophy, Duchenne
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A